Cover Image
市場調查報告書

C型肝炎病毒 (HCV) 外膜蛋白E2:開發中產品分析

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364864
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
C型肝炎病毒 (HCV) 外膜蛋白E2:開發中產品分析 Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 38 Pages
簡介

本報告提供以C型肝炎病毒 (HCV) 外膜蛋白E2為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

C型肝炎病毒 (HCV) 外膜蛋白E2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Integrated BioTherapeutics, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0974TDB

Summary:

According to the recently published report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2017'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 11 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.

The report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2017' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis C Virus Envelope Protein E2 - Overview
    • Hepatitis C Virus Envelope Protein E2 - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development
    • Aviragen Therapeutics Inc
    • Integrated BioTherapeutics Inc
  • Hepatitis C Virus Envelope Protein E2 - Drug Profiles
    • BTA-074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIGB-230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C (strain H77) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C (virus-like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBL-HCV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit E2 for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis C Virus Envelope Protein E2 - Dormant Products
  • Hepatitis C Virus Envelope Protein E2 - Discontinued Products
  • Hepatitis C Virus Envelope Protein E2 - Product Development Milestones
    • Featured News & Press Releases
      • Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma
      • Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released
      • Jun 10, 2013: IBT and Stanford Awarded STTR
      • Aug 30, 2012: Researchers Develop Monoclonal Antibody That Prevents Hepatitis C In Animal Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Aviragen Therapeutics Inc, H2 2017
  • Pipeline by Integrated BioTherapeutics Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top